Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franz Stoiber

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Wiener Medizinische Wochenschrift (1946)|December 10, 2009
[How to use PSA in 2009]Anton Ponholzer, Franz Stoiber, Wolfgang Loidl, et al.
Molecular Imaging and Biology|November 30, 2005
Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?Martin Heinisch, Albert Dirisamer, Wolfgang Loidl, et al.
International Journal of Cancer|June 25, 2025
Clinical impact of real-time androgen receptor alteration monitoring on metastatic castration-resistant prostate cancer treatment in real-world settingsRegina Stitz, Franz Stoiber, Renè Silye, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 10, 2008
Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative studyMohsen Beheshti, Reza Vali, Peter Waldenberger, et al.
Radiology|February 24, 2010
18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patientsMohsen Beheshti, Larisa Imamovic, Gabriele Broinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trialMaria De Santis, Alexander Becherer, Carsten Bokemeyer, et al.
Wiener Klinische Wochenschrift|February 3, 2016
Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancerAnton Ponholzer, Wolfgang Loidl, Jasmin Bektic, et al.
The Journal of Molecular Diagnostics : JMD|March 24, 2024
Clinical Implementation of a Noninvasive, Multi-Analyte Droplet Digital PCR Test to Screen for Androgen Receptor AlterationsRegina Stitz, Franz Stoiber, Renè Silye, et al.
Wiener Klinische Wochenschrift|July 21, 2012
[Therapy of castration-resistant prostate cancer]Michael Rauchenwald, Thomas Bauernhofer, Maria De Santis, et al.
Clinical Genitourinary Cancer|December 13, 2024
Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre StudyDora Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Wiener Medizinische Wochenschrift (1946)|December 10, 2009
[How to use PSA in 2009]Anton Ponholzer, Franz Stoiber, Wolfgang Loidl, et al.
Molecular Imaging and Biology|November 30, 2005
Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?Martin Heinisch, Albert Dirisamer, Wolfgang Loidl, et al.
International Journal of Cancer|June 25, 2025
Clinical impact of real-time androgen receptor alteration monitoring on metastatic castration-resistant prostate cancer treatment in real-world settingsRegina Stitz, Franz Stoiber, Renè Silye, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 10, 2008
Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative studyMohsen Beheshti, Reza Vali, Peter Waldenberger, et al.
Radiology|February 24, 2010
18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patientsMohsen Beheshti, Larisa Imamovic, Gabriele Broinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trialMaria De Santis, Alexander Becherer, Carsten Bokemeyer, et al.
Wiener Klinische Wochenschrift|February 3, 2016
Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancerAnton Ponholzer, Wolfgang Loidl, Jasmin Bektic, et al.
The Journal of Molecular Diagnostics : JMD|March 24, 2024
Clinical Implementation of a Noninvasive, Multi-Analyte Droplet Digital PCR Test to Screen for Androgen Receptor AlterationsRegina Stitz, Franz Stoiber, Renè Silye, et al.
Wiener Klinische Wochenschrift|July 21, 2012
[Therapy of castration-resistant prostate cancer]Michael Rauchenwald, Thomas Bauernhofer, Maria De Santis, et al.
Clinical Genitourinary Cancer|December 13, 2024
Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre StudyDora Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter, et al.
Pageof 2